Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • Addex Therapeutics' Total Liabilities rose 3437.47% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 3437.47%. This contributed to the annual value of $1.1 million for FY2024, which is 7077.18% down from last year.
  • As of Q3 2025, Addex Therapeutics' Total Liabilities stood at $1.7 million, which was up 3437.47% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Total Liabilities ranged from a high of $5.4 million in Q1 2024 and a low of $1.1 million during Q4 2024
  • In the last 4 years, Addex Therapeutics' Total Liabilities had a median value of $3.2 million in 2023 and averaged $3.0 million.
  • As far as peak fluctuations go, Addex Therapeutics' Total Liabilities soared by 5481.37% in 2024, and later plummeted by 7548.82% in 2025.
  • Over the past 4 years, Addex Therapeutics' Total Liabilities (Quarter) stood at $3.5 million in 2022, then increased by 12.71% to $3.9 million in 2023, then tumbled by 71.01% to $1.1 million in 2024, then skyrocketed by 50.12% to $1.7 million in 2025.
  • Its Total Liabilities was $1.7 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.3 million in Q1 2025.